Dr. Mark Dybul, of the National Institute of Allergy and Infectious Diseases (NIAID) and the study author, noted that this approach together with high patient adherence could be a powerful and cost-effective tool in HIV treatment.
Since shingles is very common in HIV-infected children, the NIAID and NICHD also launched a clinical study to determine whether Varivax can prevent shingles in HIV-infected children who have had chickenpox.